Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$16.97
-5.02 (-22.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-6.1M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
-95.8%
↓Gross Margin
24.9%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+172.3%
FCF CAGR
—
FCF margin
-726.5%
FCF / Net income
1.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $836664.0 · net income $-4.1M · FCF $-6.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $836664.00 | $836664.00 | $423683.00 | $2.6M | $41431.00 |
| Net Income | $-4.1M | $-4.1M | $-32.3M | $-11.7M | $-8.1M |
| EBITDA | $-3.0M | $-3.0M | $-3.4M | $-4.4M | $-2.2M |
| EPS | -276.33 | -276.33 | -32275.07 | -18955.57 | -15850.29 |
| Gross Margin | 24.9% | 24.9% | 14.0% | 124.8% | -3.8% |
| Operating Margin | -523.8% | -523.8% | -863.6% | -770.2% | -6203.4% |
| Net Margin | -489.6% | -489.6% | -7617.7% | -445.0% | -19625.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | -1.04 | 0.14 | -4.35 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.1M | $-6.1M | $-1.5M | $-11.8M | $-7.1M |
| Returns | |||||
| ROE | -95.8% | -95.8% | 842.9% | -43.3% | 369.4% |
| Valuation | |||||
| P/E | 0.02 | 0.02 | — | — | — |
| P/B | 0.06 | 0.06 | — | 0.22 | — |
| Growth & Yield | |||||
| Revenue Growth | 97.5% | 97.5% | -83.8% | 6223.0% | — |
| EPS Growth | 99.1% | 99.1% | -70.3% | -19.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-79.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-32275.07 → -276.33
Residual
-79.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.